March 2018

Important New Products

• Cabometyx (cabozantinib) inhibits multiple receptor tyrosine kinases implicated in tumour ...(more)
• Fluzone High-Dose (inactivated trivalent influenza vaccine (split virion)) contains 180 ...(more)

New Indications

• Abilify Maintena (aripiprazole) is now indicated as monotherapy for maintenance treatment ...(more)
• Keytruda (pembrolizumab (rch)) is now indicated as monotherapy for the treatment of locally ...(more)
• Orencia (abatacept (rch)) is now indicated for the treatment of active psoriatic arthritis ...(more)
• Stivarga (regorafenib) is now indicated for the treatment of hepatocellular carcinoma ...(more)
• Victoza (liraglutide (rys)) is now indicated as an adjunct to diet and exercise for treatment ...(more)
• Vyvanse (lisdexamfetamine dimesilate) is now indicated for the treatment of moderate to ...(more)

New Contraindications

• Acarizax (house dust mites Dermatophagoides pteronyssinus and Dermatophagoides ...(more)
• Burinex (bumetanide) is now contraindicated with hepatic encephalopathy.
• Diane-35 ED, Juliet-35 ED (cyproterone acetate/ethinylestradiol), Qlaira (dienogest/ ...(more)
• Movapo PFS (apomorphine hydrochloride hemihydrate) is now contraindicated for children ...(more)
• Nurofen Plus (ibuprofen/codeine phosphate hemihydrate) is now contraindicated with active ...(more)
• Renitec (enalapril maleate) is now contraindicated in combination with a neprilysin ...(more)

Active Ingredient Naming Changes

In this release, MIMS Australia will be including the following INNs (International Non-proprietary Names) as well as Australian Approved Names (AANs) as part of our push to support the Therapeutic Goods Administration (TGA) active ingredient name changes project.  

MIMS will begin referring to these ingredients by their new names, however, users may continue to search by the old AANs if preferred. ...(more)